TAGON M FORTE 10 (Metformin (1000mg) + Teneligliptin (20mg))

Tagon-M Forte Tablet ER is a combination medication designed to manage elevated blood glucose levels in individuals diagnosed with type 2 diabetes mellitus. By effectively controlling blood sugar levels, it aims to prevent severe complications associated with diabetes, such as renal impairment and vision loss, while also potentially lowering the risk of cardiovascular events like heart attacks and strokes. This medication can either be administered as a standalone treatment or in conjunction with other antidiabetic agents. Optimal results are best achieved when the medication is integrated into a comprehensive management plan that includes a balanced diet and consistent physical activity. The prescribed dosage is individualized, based on the patient’s specific medical condition, current blood sugar metrics, and any additional medications being taken. To minimize the likelihood of gastrointestinal discomfort, it is advisable to take this medication with food. Regular adherence to the prescribed regimen is crucial for maximizing its therapeutic benefits, and discontinuation should only occur under a healthcare professional’s guidance. It is also essential to continue following the dietary and exercise recommendations provided by the healthcare provider since lifestyle modifications play a significant role in effective diabetes management. Common adverse effects associated with this medication may include gastrointestinal symptoms such as diarrhea, nausea, vomiting, as well as headaches. Additionally, patients using other antidiabetic treatments, such as insulin or sulfonylureas, should be aware of the risk of hypoglycemia and be equipped to recognize and manage it appropriately. Prior to initiating treatment, patients must inform their healthcare provider if they have a history of renal, hepatic, or cardiovascular issues, pancreas-related problems, or high alcohol consumption. Pregnant or nursing individuals should also seek medical advice before starting this therapy. Regular evaluation of kidney function and blood glucose levels will be performed by the healthcare provider during the treatment course.